文献速递细菌感染、耐药与抗菌药物医院感染防控

全球铜绿假单胞菌队列中头孢地尔敏感性降低及交叉耐药的基因组与临床特征

Genomic and Clinical Features Associated With Reduced Susceptibility to Cefiderocol and Cross-Resistance to β-Lactam/β-Lactamase Inhibitors in a Global Cohort of Pseudomonas aeruginosa.
PubMed 文献 · J Infect Dis · 2026-01-01

研究纳入10国POP研究中186株碳青霉烯耐药铜绿假单胞菌(CRPA),行全基因组测序、头孢地尔微量肉汤稀释和群体分析谱。11株(5.9%)对头孢地尔不敏感、28株(15.1%)异质性耐药(CLSI);敏感性降低与PirRS调控的铁载体受体改变、AmpC突变、cpxS突变及blaNDM、blaVEB相关。头孢地尔耐药在异质性耐药株而非敏感株中于人体模拟暴露下出现。

要点

  • 全球CRPA中头孢地尔敏感性降低检出率为5.9%不敏感、15.1%异质性耐药(CLSI)。
  • 头孢曲唑/他唑巴坦和头孢他啶/阿维巴坦耐药独立关联头孢地尔敏感性降低。
  • 异质性耐药株在人体模拟头孢地尔暴露下可筛选出耐药。

核心结论

  • 头孢地尔敏感性降低呈全球分布,不限于克隆高危谱系,作为多重耐药铜绿假单胞菌挽救方案的可行性令人担忧。

研究设计与样本

  • 前瞻性观察性铜绿假单胞菌(POP)研究,从10国972例患者中选取186株临床CRPA分离株。
  • 采用全基因组测序、头孢地尔微量肉汤稀释和群体分析谱进行表征。
  • 用中空纤维感染模型评估人体血清模拟头孢地尔暴露下耐药的出现。

主要发现

  • 186株中,CLSI折点下11株(5.9%)对头孢地尔不敏感,28株(15.1%)异质性耐药。
  • EUCAST折点下20株(10.8%)对头孢地尔耐药,20株(10.8%)异质性耐药。
  • 敏感性降低分离株存在于所有地理区域,携带PirRS调控铁载体受体改变、与头孢曲唑/他唑巴坦敏感性降低相关的AmpC β-内酰胺酶突变、cpxS突变及blaNDM和blaVEB。
  • 对头孢曲唑/他唑巴坦和头孢他啶/阿维巴坦的耐药独立关联头孢地尔敏感性降低。
  • 头孢地尔耐药在异质性耐药株而非敏感株中于人体模拟暴露下出现。

关键数值与推荐

  • 头孢地尔敏感性降低定义为群体分析异质性耐药,或按当前折点判为中介/耐药。
  • CLSI折点下:不敏感11/186(5.9%),异质性耐药28/186(15.1%)。
  • EUCAST折点下:耐药20/186(10.8%),异质性耐药20/186(10.8%)。

临床怎么用

  • 对多重耐药铜绿假单胞菌使用头孢地尔前应关注头孢曲唑/他唑巴坦和头孢他啶/阿维巴坦耐药史。
  • 需警惕异质性耐药,常规药敏可能漏检,必要时加做群体分析谱。

局限性

  • 分离株选自POP研究972例患者中的186株,非全部连续菌株。
  • 异质性耐药与耐药定义依赖CLSI和EUCAST折点,结果随折点不同而异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cefiderocol retains high rates of activity against carbapenem-resistant P. aeruginosa (CRPA) and is being introduced as a last resort antibiotic in developing countries. This study assessed the clinical and genotypic characteristics associated with decreased cefiderocol susceptibility among a global collection of CRPA isolates. METHODS: Clinical isolates (n = 186) selected from 972 patients enrolled from 10 countries as part of the Prospective Observational Pseudomonas (POP) study were characterized by whole-genome sequencing, cefiderocol broth microdilution, and population analysis profile. We compared clinical and genomic characteristics between susceptible isolates and those with reduced cefiderocol susceptibility (defined as heteroresistant by population analysis, or intermediate or resistant using current breakpoints). A hollow fiber infection model was used to evaluate the emergence of resistance under human serum simulated cefiderocol exposures. RESULTS: Of the 186 isolates, 11 (5.9%) were cefiderocol nonsusceptible and 28 (15.1%) were heteroresistant using CLSI breakpoints. With EUCAST breakpoints, 20 (10.8%) were cefiderocol resistant and 20 (10.8%) were heteroresistant. Reduced susceptibility isolates were present across all geographic regions and harbored changes in PirRS-regulated siderophore receptors, AmpC β-lactamase mutations associated with decreased ceftolozane/tazobactam susceptibility, cpxS mutations, and the β-lactamases blaNDM and blaVEB. Resistance to ceftolozane/tazobactam and ceftazidime/avibactam were independently associated with reduced cefiderocol susceptibility. Cefiderocol resistance emerged in a heteroresistant, but not susceptible isolate at human simulated exposures. CONCLUSIONS: Decreased cefiderocol susceptibility is present worldwide and is not restricted to a clonal high-risk lineage. This raises concerns about the use of cefiderocol as a salvage regimen in patients with multidrug-resistant P. aeruginosa infection.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Egge SL, Kang D, Pouya N, et al. Genomic and Clinical Features Associated With Reduced Susceptibility to Cefiderocol and Cross-Resistance to β-Lactam/β-Lactamase Inhibitors in a Global Cohort of Pseudomonas aeruginosa. J Infect Dis. 2026. PMID: 42140752. doi:10.1093/infdis/jiag263

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。